Myriad Genetics (MYGN) Tops Q1 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Myriad Genetics (MYGN) Tops Q1 EPS by 13c

Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results

November 6, 2018 4:05 PM EST

Total First-Quarter Revenues of $202.3 Million, Up 13 PercentFirst-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 PercentRevised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of $1.70 to $1.75

SALT LAKE CITY, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal first-quarter 2019, provided an update on recent business highlights, revised its fiscal year 2019 financial guidance and provided fiscal second-quarter 2019 financial... More